banner
mlockley.bsky.social
Michelle Lockley
@mlockley.bsky.social
500 followers 420 following 3 posts
Medical oncologist and scientist, into all things ovarian cancer. In search of the answer to cancer drug resistance
Posts Media Videos Starter Packs
mlockley.bsky.social
Michelle Lockley @mlockley.bsky.social · May 2
Oops, here you go: aacrjournals.org/cancerres/ar...
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...
aacrjournals.org
1
Reposted by Michelle Lockley
trevorgraham.bsky.social
Trevor Graham @trevorgraham.bsky.social · May 2
With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...

@icr.ac.uk @qmbci.bsky.social
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...
aacrjournals.org
2 6 36
Reposted by Michelle Lockley
trevorgraham.bsky.social
Trevor Graham @trevorgraham.bsky.social · May 2
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...
Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...
bmjopen.bmj.com
1 2 4
Reposted by Michelle Lockley
qmbci.bsky.social
Barts Cancer Institute (Queen Mary University of London) @qmbci.bsky.social · Apr 30
📰 Can we use the power of evolution to improve ovarian cancer survival?

A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.

Read more ➡️ www.bci.qmul.ac.uk/general-news...

#AACR25 #medsky #oncosky🧪
Smarter chemotherapy approach could delay drug resistance in ovarian cancer - Barts Cancer Institute - Queen Mary University of London
Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian canc...
www.bci.qmul.ac.uk
3 7 19
mlockley.bsky.social
Michelle Lockley @mlockley.bsky.social · Apr 30
Can we use the power of evolution to improve ovarian cancer treatment? Our latest paper says yes! Online now at Cancer Research. Thanks to
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.
1 3 9
mlockley.bsky.social
Michelle Lockley @mlockley.bsky.social · May 28
Delighted to speak at Moffitt Cancer centre last week. Great to share our research and really enjoyed the thought provoking discussions. Many thanks to Joel brown for hosting
1 5